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Abstract: Early detection of prostate cancer is problematic, not just because of uncertainly 
whether a diagnosis will benefit an individual patient, but also as a result of the imprecise 
and invasive nature of establishing a diagnosis by biopsy. Despite its low sensitivity and 
specificity for identifying patients harbouring prostate cancer, serum prostate specific 
antigen (PSA) has become established as the most reliable and widely-used diagnostic 
marker for this condition. In its wake, many other markers have been described and 
evaluated. This review focuses on the supporting evidence for the most prominent of these 
for detection and also for predicting outcome in prostate cancer. 
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1. Introduction  
Prostate cancer (PCa) is now the most commonly diagnosed internal cancer in the western world 
and the second most lethal male malignancy. Prior to clinical availability of a blood test for prostate 
specific antigen (PSA) in the mid 1980s, most PCa patients were diagnosed with more advanced disease.  
Advances in surgical and radiation therapies now result in cure for a proportion of patients who 
would not have benefitted from combination PSA/digital rectal examination (DRE)-based detection in 
the past. However, from a public health perspective, indiscriminate PSA population screening cannot 
be justified because of the low sensitivity and specificity of this blood test in identifying cancer, 
amongst other concerns [1]. Furthermore, there is prevailing uncertainty on the basis of the PSA blood 
test as to who will benefit from treatment with curative intent [2–5]. Recognition of these shortcomings 
has focussed research into markers to detect the presence of PCa and, more importantly, to try to 
discriminate between those patients harbouring indolent as opposed to aggressive disease including 
those for whom any form of local therapy will not prevent subsequent declaration of metastases. 
There is a clinical imperative in being able to identify those who do and do not have PCa since, 
apart from the obvious advantage from detecting and treating the condition at the earliest stage 
possible, the diagnostic process itself is not without its problems. Suspicion of the presence of PCa, 
alerted as a result of an abnormal serum PSA and/or and abnormal DRE, requires an invasive 
procedure to provide histological confirmation with biopsies (usually >12) almost always obtained via 
imaging with a transrectal ultrasound (TRUS) probe to ensure spatial positioning of biopsy needles. 
The majority of men who have prostatic biopsies do not have PCa diagnosed but continue to have 
raised serum PSA levels with ongoing concerns of a possible undetected PCa due to the imprecise 
nature of both the PSA test and TRUS biopsies. US Medicare-SEER analyses 1993 to 2001 indicated 
that, among men whose first recorded biopsy did not detect cancer, the likelihood of undergoing 
subsequent biopsies was 11.6% at 1 year and 38% at 5 years [6]. In addition, although the dreaded 
complication of life-threatening sepsis is fortunately uncommon but reported to be increasing [7], 
~50% experience lesser symptoms after TRUS biopsy so diagnosing PCa remains problematic for 
many reasons. Consequently, it is not surprising that the need to be able to detect prostate cancer by a 
simple and reliable approach which can be repeated easily over time, is a diagnostic priority in the 
western world. 
2. Scope of the Review 
The strengths and weaknesses of PSA in the detection of PCa have been examined and published 
extensively and, since the topic has been reviewed very recently by Roobol et al. [8], who 
comprehensively examined the relevant medical literature with respect to the risk of developing PCa, 
this dissertation will not re-visit this marker. These authors reported that, despite its limitations, 
published evidence indicates that total serum PSA is the single most significant clinically-used 
predictive factor for identifying men at increased risk for PCa. Total PSA was superior to percentage 
free PSA, PSA velocity and Human kallikrein 2 (hK2), the most studied kallikrein protein after PSA 
(hK3) itself. A suspicious DRE, a family history of PCa, the presence of high grade prostatic 
intraepithelial neoplasia (HGPIN) or atypical small acinar proliferation (ASAP) and black ethnicity 
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also were reported to be important predictive factors. For men of screening age (50 to 70 years) a 
serum PSA of greater than 1.5 ng/mL has been found to indicate a greater than average risk up to 8 
years (7.5-times greater risk vs. 1.5 ng/mL or less) for developing PCa [8]. In terms of diagnosing 
established PCa, PSA cut-offs are useful with the likelihood of men harbouring PCa greater the higher 
the level of serum PSA. However, it is important to note that PSA is a continuous variable and that a 
proportion of patients with low serum PSA levels <4 ng/mL have PCa of clinical significance [9].  
Histological interpretation too has advanced with the Gleason scoring criteria agreed upon at the 
WHO ISUP consensus meeting in 2005 [10,11] being more useful clinically than those criteria with 
Gleason grading used previously. Much has been published in the Uro-pathology literature in relation 
to histological nuances in addition to describing a range of tissue biomarkers for PCa characterisation. 
These include apoptotic factors such as p53 and Bcl-2, the androgen receptor (AR), signal transduction 
factors within the EGF receptor family, cell cycle regulators exemplified by c-Myc, p16, p27, pRb and 
Ki67, cell adhesion and cohesion factors and factors involved in neo-angiogenesis, such as vascular 
endothelial growth factor (VEGF), VEGF receptors and nitric oxide [12,13]  
Histopathology will not be addressed further nor will imaging adjuncts to biopsy. However, in 
interpreting the value of diagnostic biomarkers from biological fluids, which is the subject of this 
review, accurate histology and appropriate targeting with biopsy needles are essential. It is particularly 
important to be aware that the diagnostic biopsy reference on which biological fluid biomarkers are 
judged is deficient, varying with sites targeted and numbers of biopsies obtained, ranging in one study 
from 31.7% for sextant biopsies to 38.7%, 41.5%, and 42.5% for 12, 18 and 21 cores respectively in a 
study of 1000 patients [14].  
Accurately determining the presence of disease is surprisingly difficult. Autopsy studies permit 
exhaustive and comprehensive scrutiny of the prostate histologically but are flawed in terms of clinical 
relevance for epidemiological reasons. True incidence derived from more epidemiologically-vetted 
clinical trials is almost non-existent given the rarity of complete cross-sectional ‘end of study 
biopsies’. Sakr found in autopsy studies that, for the third through to the eighth decades of life, the 
incidence of PCa in a cohort of 1051 subjects was 7, 23, 39, 44, 65 and 72% [15].  
Haas et al. [16] performed 18 core biopsies on autopsy prostates from 164 men who had no history 
of PCa. They reported that six-core biopsies were taken from each of the mid peripheral zone (MPZ), 
the lateral peripheral zone (LPZ), and the central zone (CZ). PCa was present in 47 (29%) prostates. Of 
the 47 cancers detected, 20 were clinically significant according to histologic criteria. Biopsies from 
the CZ did not detect any cancer that was not present in biopsies from either the MPZ or LPZ. The 
sensitivities of biopsies from the MPZ for clinically significant and insignificant cancer were 55% 
(95% CI = 32% to 77%) and 11%, respectively, compared with 80% and 33% for those from the MPZ 
and LPZ combined. In a single institutional study, Djavan et al. [17] found in an assessment of repeat 
biopsies that PCa was present in 22% (231/1051), 10% (83/820), 5% (36/737) and 5% (4/94) of first, 
second, third and fourth biopsies. Together with others, these studies illustrate the fact that the 
reference by which the sensitivity and specificity of biomarkers are judged is well short of perfect and 
this deficiency also should be borne in mind in assessing the predictive values of potential biomarkers. 
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3. Sources for Biomarker Analyses 
A number of tissue/fluid sources and approaches have been employed in the quest to develop a non-
invasive diagnostic test for PCa. These range from analysing tears [18]
 
to changes in the odour of urine 
detected by dogs [19]
 
but, in terms of commonly studied sources, prostatic fluid and blood have 
received most attention. Patient acceptance of venesection for taking samples of blood (for analysis as 
whole blood or serum) and providing urine is extremely high and laboratory staff are so conversant 
with the properties of both that they do not warrant detailed discussion in this manuscript. 
However, the use of prostatic fluid is not nearly as well appreciated. It is logical that fluid and/or 
cells obtained as directly as possible from the PCa itself should have differences in greatest abundance 
to those from normal prostates. Prostatic fluid may be obtained either as post-prostatic massage urine 
or ejaculate and/or post-ejaculate urine.  
3.1. Post-Prostatic Massage Urine 
Since DRE by itself dislodges too few retrievable prostatic cells, most studies using prostatic fluid 
have obtained specimens for analysis by prostatic massage [20–29] which is recommended to involve 
3 sweeps per lobe, optimally depressing the prostate by 0.5–1 cm in a milking action to ensure 
sufficient numbers of prostatic cells are obtained [30]. Micturition following massage then washes 
prostatic fluid and cells dislodged into the prostatic urethra to the external meatus for collection. 
Although there is a low likelihood of testicular cells or sperm being collected with this approach, 
one limitation is that only the MPZ is directly targeted for massaging with the anterior LPZ missed 
completely. In addition to being unpleasant, a further potential problem with vigorous prostatic 
massage is dislodging cancer cells into the systemic circulation with possible adverse consequences in 
terms of facilitating metastatic spread although evidence at 5 years does not support accelerated cancer 
evolution judged as a result of blood seeding cancer cells during operative intervention [31]. 
Figure 1. Ultrasound probe in rectum illustrating the relative relationship of rectum and 
prostate: white arrows indicate the transition zone (TZ). 
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3.2. Ejaculate 
Prostatic fluid with disaggregated cells in ejaculate is expelled during orgasm following contraction 
of prostatic smooth muscle, distributed widely throughout the gland. In addition to the prostatic 
component, ejaculate contains contributions from the testes, epididymi and seminal vesicles and there 
is a tendency for a reduction in ejaculate volume with ageing. Certainly, following resection of the 
bladder neck with transurethral resection of prostate (TURP), there is retrograde emission so that 
seminal fluid mixes with urine to be expelled subsequently during micturition.  
Much has been made of a reduced capability of older men to be able to perform but evidence in the 
medical literature [32,33] is to the contrary. Our experience has been that when the request is optional 
and not directly related to management outcome, a proportion of patients, although capable, will elect 
not to comply in producing a specimen in private and returning it promptly to the laboratory but, if 
there is a diagnostic imperative such as a sperm analysis, the response is quite different. Therefore, 
using ejaculate as a preferred body fluid for PCa testing is considered a practical option. 
 Impotence does not exclude an ability to ejaculate although firm tumescence certainly helps with 
this process. It is notable that erectile dysfunction is now well-recognized as a sentinel event for 
underlying cardiovascular disease and has been reported to be a predictor for the combined outcome of 
acute myocardial infarction, stroke and sudden death [34]. Therefore, an inability to ejaculate may 
translate as a surrogate for identifying a subset of patients for whom a diagnosis of PCa is less likely to 
affect life expectancy in the context of what is a relatively slowly progressing malignancy in the 
majority of cases.  
4. Identifying Discriminating Markers 
Although the cause of PCa continues to remain elusive, family histories indicate a strong inherited 
genetic predisposition in both the risk of developing PCa and the likelihood of a poor outcome should 
PCa be present. Not only is a family history of PCa with early age of onset and numbers of first degree 
relatives especially relevant in identifying predisposition [35], but a family history of breast cancer is 
also emerging as important especially in relation to BRCA2 mutations. Certainly, BRCA2 mutations 
are reported to be uncommon in sporadic PCa, estimated as <1% in US patients and 2.3% in UK  
patients [36] and also not common in hereditary PCa [37]. However, men who do develop PCa and 
harbour a BRACA2 mutation are more likely to have aggressive tumours and tend to develop these 
malignancies at an earlier age than other patients [36,38].  
Genome-wide association studies (GWAS) indicate genetic heterogeneity for the onset of disease 
with numerous low risk loci described along with two notable high-risk loci at 8q24 and 7q31. The 
linked loci on 8q24 are located immediately downstream of the MYC gene that is upregulated in  
PCa [39,40]
 
and linkage at 7q31 in African American men is in close proximity to the PODXL  
gene [41] which has been mutated in men with aggressive forms of the disease [42]. It is noteworthy 
that a combination of a family history of PCa together with genetic SNP variations increases the risk 
association significantly. In addition to genetic heterogeneity there is also a high likelihood that PCa 
genes/alleles act cooperatively in the aetiopathogenesis of the disease supporting the notion that it is 
unlikely that any one biomarker alone is likely to be conclusive in detecting and predicting outcome. 
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The Practical consortium recently reported the conclusion of their successive GWAS studies. They 
evaluated over 500,000 alleles (SNPs) in 3 separate cohorts of cases/controls (up to 30,000 men [43]. 
The consortium eventually identified alleles in 7 genomic regions (encompassing 11 genes) that were 
linked to PCa diagnosis. The allele penetrance ranged from 6–50% of the population and each allele 
altered PCa risk by 0.35–1.89 (odds ratio). 
Chromosomal aberrations are very common in prostate tumours [44] and may act together in the 
progression of the disease. For example, the loss of both the PTEN gene on chromosome 10q and a 
recurrent 30Mb deletion on 21q, that leads to the fusion of TMPRSS2 and ERG (see section on ETS 
fusions), are common aberrations which appear to act together in disease progression [45]. Gain and 
amplification of the MYC gene on 8q24 [44,46] is of great interest especially given the strong GWAS 
linkage established immediately downstream of the gene [39,40].  
5. Assay Approaches & Most Promising Markers  
In reaching the current position with respect to identifying markers of detection, RNA profiling 
using microarray-based technologies has been particularly useful in tracking changes in gene 
expression during tumorigenesis. To date, the two most prominent candidate RNA biomarkers are the 
PCA3 gene and TMPRSS2 fusion transcripts. These, together with other genetic and non-genetic 
markers, are discussed below with respect to their likelihood in differentiating cancer from non-cancer 
and identifying indolent as opposed to aggressive and life-threatening tumours. 
Given the many markers reported in the scientific literature, we have had to follow the practice 
employed in other reviews of selecting a short list of those which are considered to be most relevant 
and most promising. 
5.1. Markers of Detection versus Prognosis 
Arguably far more important than a diagnosis of PCa is the true nature of the condition in an individual 
patient. Although, without doubt, timely intervention does save lives, it is indisputable that many men 
who have treatment with curative intent for PCa are unlikely to benefit in terms of survival [47–49]. 
However, all these patients are at-risk of not inconsiderable side effects from intervention including 
previously unrecognised problems afflicting both them and, indirectly, their loved ones [50–53]. 
Contemporarily, the large majority of patients are diagnosed with PCa as a result of PSA testing and 
~30% are stratified to low-risk disease with another ~25% already having occult metastases which 
declare themselves subsequently [54,55]. Because of the disparity between TRUS biopsy findings and 
those of whole-gland histology, there is a tendency for many urologists and patients to err on the side 
of intervention and to proceed to treatment with curative intent, accepting that a significant proportion 
of patients will have treatment that will not affect survival or benefit their well-being. 
In order to identify the minority of patients stratified as having low-risk PCa following biopsy but 
whose disease is likely to progress, Klotz initiated an active surveillance protocol [55]
 
undertaking a 
period of very intense 2-year monitoring of these men with PSA testing, DRE and at least yearly 
TRUS biopsies to unearth the ~25% of men who actually have more aggressive disease not evident 
from initial TRUS biopsies [55]. This approach has been emulated by colleagues in the UK, US and 
Europe and a randomised study has been undertaken to examine this strategy further, in the 
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Surveillance Therapy Against Radical Treatment (START) trial. Klotz has the largest and most mature 
study of active surveillance and has reported an 85% overall survival and 99% disease specific survival 
with a median follow-up of 8 years (range 2–11 years) [55]. Clearly there is an overwhelming need for 
a prognostic profile that would, non-invasively, permit accurate stratifying of PCa patients. 
A distinction between detection, prediction and prognosis is not clear for many of the markers 
reported with some having the potential to fulfil both roles. Identification of potential markers has been 
based largely on histological expression of candidates but, interestingly, it is common for a disparity to 
exist between tissue expression and detection in various biofluids [56]. Furthermore, although many of 
the biomarkers identified have been at a protein level or produce protein(s)/peptides, there are many 
such as microRNAs, non-coding RNAs and metabolic products not directly associated with proteins or 
peptides contributing to the pot-pourri of potentially useful biomarkers for identifying the presence and 
nature of PCa non-invasively. 
6. Comments on Selected Genetic Markers 
A selection of biomarkers is listed in tables 1 & 2 (below). For the multivariate analysis, AIC-based 
backward selection was used to drop insignificant terms. 
Table 1. Post-prostate massage-urine biomarkers for the detection of prostate cancer from 
Laxman et al. [26]. 
Variable Coefficient P 
Univariate logistic regression analysis 
GOLPH2 0.4444 0.0002 
SPINK1 0.25 0.0002 
PCA3 0.187 0.001 
TMPRSS2:ERG 0.609 0.034 
ERG 0.043 0.166 
TFF3 0.11 0.189 
PSA (serum) 0.0151 0.376 
AMACR 0.049 0.45 
Multivariate logistic regression analysis 
SPINK1 0.308 7.41E-05 
PCA3 0.191 0.003 
GOLPH2 0.372 0.004 
TMPRSS2:ERG 0.924 0.006 
Table 2. Potential urine markers for monitoring prostate cancer, modified from 
Jamaspishvili et al. [57]. 
Symbol Description 
Type of marker 
Ref. 
Body 
Fluid DNA  RNA  Protein  Metabolite  
8-OhdG  8- HydroxydeoxyguanosineU +   + [58] U 
ANXA3 Annexin A3   +  [59–62] PD 
BHUAE  Basic human urinary  
arginine amidase 
  +  [63] U 
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Table 2. Cont. 
F3 Coagulation factor III 
(thromboplastin,  
tissue factor) 
  +  [64] U 
GSTP1 Glutathione S-transferase P 1 +    [65–69] PM 
LOH  Loss of heterozygosity  
e.g., loss of PTEN 
+    [70,71] PM 
MCM5 Minichromosome 
maintenance complex 
component 5 
  +  [72] U 
MMP9 Matrix metalloproteinases 9   +  [73–75] U 
PIP  Prostatic inhibin-like peptide   +  [76] U 
PSA Urinary prostate specific 
antigen 
  +  [77] U 
S100A9 S100 calcium binding protein 
A9 (alias calgranulin B) 
  +  [78] PM 
SAR  Sarcosine    + [79] PD 
SRD5A2 Steroid 5-alpha-reductase 
type 2 
  +  [80] U 
TERT Telomerase reverse 
transcriptase 
 +   [81–83] PM 
TMSB15A Thymosin beta 15a   +  [84] U 
VEGF Vascular endothelial  
growth factor 
  +  [85,86] U 
Key: PM~ post-prostate-massage urine, PD ~ post digital examination urine, U~ voided urine. 
6.1. PCA3 
PCA3, previously known as DD-3, is a non-coding gene first reported by Bussemakers et al. [87]. 
mRNA of the PCA3 gene is highly over-expressed (median 66-fold) in >95% of PCa tissue compared 
with normal or benign prostatic tissue of the same patients [20,87]. PCA3 has been assayed from urine 
following prostatic massage in 11 separate clinical studies totalling 2737 men from Western  
countries [21–24,28,30,88–93] with an overall sensitivity of 69% and specificity of 70% for men  
with PCa. 
The role of PCA3 in clinical practice as a commercially-available test remains uncertain with most 
advocates indicating a place in patients who have already had TRUS biopsies with a negative result for 
cancer but in whom PCa remains suspected. Another application may be as an adjunct to repeat DREs, 
serum PSA estimations and prostatic biopsies in following men diagnosed with low-risk PCa who have 
elected to be monitored carefully in active surveillance protocols rather than have treatment with 
curative intent. However, more recently, a number of investigators have combined their PCA3 findings 
with those from other markers to try to incrementally improve detection rates since it is clear that no 
one marker by itself is adequate for detecting all cases of PCa. 
Cancers 2010, 2              
 
 
1133 
6.2. PCA3 Redefined 
Although upregulation of PCA3 was first described in PCa specimens in 1999 [87], it was another 
10 years before the complete structure of the gene was resolved [94] with description of new start sites, 
additional exons and a range of novel alternatively-spliced transcripts (Figure 2), some of which are 
more highly enriched in PCa and metastases, expression not normally being seen outside the prostate. 
PCA3 is embedded in an anti-sense orientation within an intron of another much larger gene,  
BMCC1-1. In contrast to PCA3, a weakly conserved non-coding gene, BMCC1-1 has a conserved protein 
domain with an established role in Rho-signalling, cellular transformation and metastasis [94,95]. 
PCA3 expression is androgen responsive with alternatively spliced PCA3 mRNA transcripts 
differentially upregulated in up to 95% of PCas and metastases [94–96]. PCA3 mRNA levels have 
been detected in primary and metastatic PCa tissue specimens at up to 43 and 110 times the levels 
expressed in normal prostate tissue, respectively, compared with up to a 3 fold increase in benign 
prostatic hyperplasia (BPH) [94]. By combining PCA3 with 2 other biomarkers (i.e., PSMA and 
hepsin) 100% of tissue samples (55 in total) were classified as either PCa or BPH [97]. The recent 
discovery of novel PCA3 transcripts, inclusive of exons 2a and 2b, that are more highly enriched in 
PCa and metastases and the identification of complementary biomarkers [26,97] tantalises 
investigators who seek further improvements in PCa detection and characterisation through a non-
invasive molecular approach. 
PCA3 is expressed at high levels in metastatic PCa but, empirical data do not support an association 
between PCA3 upregulation and clinical stage, Gleason scores, tumour volume, pathological stage or 
cancer progression [93,98]. Nevertheless, the genomic inter-relationship between PCA3 and the 
different BMCC1 isoforms [94] may not be coincidental and investigations are underway for clues to the 
association between BMCC1 regulation and PCa initiation and progression [94]. 
Figure 2. Redefined PCA3 gene. 
 
The truncated form of PCA3 described by Bussemakers et al. [87]
 
was extended by Clarke et al. [94]
 
using a thorough 5’ and 3’ RACE analysis of the mature message and DNA and RT-PCR sequencing 
in their description of the complete PCA3 gene with: 
 Exon 1 over 10 times longer than previously reported 
 4 new transcription start sites 
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 4 polyadenylation sites 
 2 new differentially spliced exons 
 PCA3 embedded in intron 6 of the BMCC1-1 gene 
6.3. ETS Gene Fusions 
ETS gene fusion provides a highly specific biomarker assay for the detection and prognosis of PCa. 
In 2005, microarray analyses identified two E26 avian erythroblastosis virus (ETS) family 
transcription factors, ETS related gene (ERG) and ETS variant gene 1 (ETV1), as potentially important 
PCa biomarkers [99]. Aberrant expression of these ETS genes was found coincident with gene fusion 
between the 5′ untranslated region of androgen-regulated transmembrane protease, serine 2 (TMPRSS2) 
gene and the ETS genes ERG (chromosome 21q22.2), ETV1 (7p21.2), ETV4 (17q21) or ETV5 (3q28) 
or one of ~20 other gene fusion variants [100–103]. ERG and ETV1 rearrangement and overexpression 
has been reported to occur in the majority (50–60%) of PCas with the most common variant being a 
recombination between exon 1 of TMPRSS2 and exon 4 of ERG, designated T1/E4 [104–108] 
represented in ~85% of all reported fusion cases [101,109]. Identification of ETS fusions in the ‘post-
prostatic massage urines’ from men with PCa using RT-PCR has a sensitivity of 37%, a specificity of 
93%, a negative predictive value of 36% and positive predictive value of 94% [25,110,111]. 
ETS gene fusions have an important role in PCa development and prognosis. ERG and ETV1 show 
mutually exclusive overexpression in PCa tissues, suggesting a redundant function in PCa 
development. In addition, ERG and ETV1 gene fusions have been detected in only a limited number of 
BPH and High-Grade Prostate Intra-epithelial Neoplasia (HGPIN) lesions, albeit in the absence of ETS 
upregulation [112,113]. In one cohort TMPRSS2–ERG T1/E4 fusion associated upregulation of ERG 
was found to be highly prognostic of disease recurrence [114] independent of grade, stage and PSA 
level [105]. ETS fusions are strongly linked with survival when associated with loss of PTEN  
(P < 0.001) [115] and have been identified in 48% of men who died of castrate-resistant disease [116]. 
Fusion-related upregulation of ERG is increased by oestrogens and the incidence and prognostic 
significance of these gene fusions may vary with cohort race/ethnicity and different techniques of 
detection [108,115,117–121]. Electrophoresis after RT-PCR using fusion specific primers followed by 
Southern transfer and probing with fusion specific probes appears to be a more rigorous method of 
detection [110]. 
7. Other Markers of Detection 
7.1. Early Prostate Cancer Antigen 
Leman et al. [122] reported results on a serum biomarker called early prostate cancer antigen 
(EPCA) using an antibody assay against the EPCA-2.22 epitope. The study involved 385 men and 
reported a 92% specificity for healthy men and men with benign prostatic hyperplasia and a 94% 
sensitivity for overall PCa detection. In addition, the authors indicated that EPCA-2.22 was highly 
accurate in differentiating between localized and extracapsular disease [122]. More recently, the same 
group reported on a second epitope of EPCA, designated EPCA-2.19, which they found provided 
almost identical results [123]. Despite the promising nature of these findings, more details are required 
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including the results from multicentre studies. As a result of challenges to the work regarding EPCA-2, 
the place of this candidate as a PCa marker is currently uncertain [124]. 
7.2. GOLPH2 
GOLPH2/GP73, elevated in PCa tissues, is detectable in post-prostatic massage urine from PCa 
patients. GOLPH2 immunihistochemical staining indicates a perinuclear Golgi-type pattern that is 
more intense in PCa glands compared with normal glands (P < 0.001) [125]. In a large study by 
Kristiansen et al. [125], upregulation of GOLPH2 protein was reported in 567 of 614 tumours (92.3%) 
and AMACR in 583 of 614 tumours (95%) (correlation coefficient 0.113, P = 0.005). Importantly, 
GOLPH2 immunohistochemical analysis indicates a lower level of intratumoral heterogeneity (25 vs. 
45%). Further, GOLPH2 upregulation was detected in 26 of 31 (84%) AMACR-negative PCa cases. 
Using PCR analysis, Laxman et al. [26] demonstrated increased GOLPH2 levels in post prostatic 
massage urines as a significant predictor of PCa when multiplexed with PCA3 and SPINK1 [26]. 
7.3. SPINK1 
SPINK1 (also referred to as TAT1) is a biomarker for PCa that can be detected in prostatic massage 
urine. SPINK1, a trypsin inhibitor secreted from pancreatic acinar cells, is thought to function in the 
prevention of trypsin-catalyzed premature activation of zymogens within the pancreas and the 
pancreatic duct. Mutations of this gene are associated with hereditary pancreatitis and tropical calcific 
pancreatitis [127,128]. SPINK1 is also overexpressed in other cancers, and an elevated serum level is 
an independent prognostic indicator in many of these, as reviewed by Paju and Paju [129,130]. 
Tomlins et al. [126] found SPINK1 expression to be an outlier (using a meta-COPA outlier  
meta-analysis) exclusively in a subset (10%) of ETS rearrangement-negative cancers and only in 6% 
of ETS negative PCa ductal adenocarcinoma variants [131]. Laxman et al. [26] showed that a 
multiplexed qPCR assay including SPINK1 on sedimented
 
urine from patients presenting for prostate 
biopsy or prostatectomy
 
outperformed serum PSA or PCA3 alone. SPINK1 expression in urine is also 
an independent predictor of biochemical recurrence after resection [26,126]. The aggressive 22RV1 
prostate cancer cell line expresses SPINK1 and SPINK1 knockdown attenuates 22RV1 invasion, 
suggesting a functional role in ETS rearrangement-negative prostate cancers [126]. 
7.4. α-Methylacyl Coenzyme A Racemase (AMACR) 
AMACR is a very commonly used immunohistochemical marker for PCa which can also be 
detected in the urine of PCa patients [26,57,125]. AMACR, also known as P504S, is involved in  
β-oxidation of branched-chain fatty acids and fatty acid derivates. AMACR is consistently upregulated 
at both the mRNA and protein levels in prostate tissue [57], however, its usefulness as a biomarker in 
urine is controversial [26,132,133]. Western blot analysis for AMACR was used on voided urine after 
TRUS and biopsy, showing a 100% sensitivity and 58% specificity for PCa detection in one group of 
patients with negative biopsy findings [133]. 
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8. Specific Prognostic Markers 
As the second step in the non-invasive detection process, prognosticating is less well established 
with the possible exception of tissue characterisation using markers, with the presumption that the 
biopsied samples are representative of each gland’s malignancy status. Furthermore, although a 
number of markers have been reported to indicate aggressive and lethal PCa, there are considerably 
fewer indicators of low-risk PCa which is of particular relevance if an active surveillance or close 
observation clinical approach is to be pursued.  
8.1. AZGP1 & hCAP-D3 
Zinc-alpha2-glycoprotein (AZGP1) is present in high concentration in human seminal plasma and 
considered to be a soluble homologue of MHC-I [135]. Hale et al. [136] reported that Anti-AZGP1 
monoclonal antibodies reacted strongly with normal prostatic epithelium but not with other 
components of prostate or seminal vesicles and that 35 of 48 PCas also reacted with anti-AZGP1 
antibodies. However, it was notable that high-grade tumours expressed significantly less AZGP1 than 
moderate-grade tumours. In addition, men with AZGP1-producing PCas had elevated levels of serum 
AZGP1 relative to normal age- and race-matched controls (P < 0.02). More recently, Bondar et al. [137] 
have developed a serum bio-assay for AZGP1 [137]. 
Henshall et al. [138] reported on the highly predictive capacity of AZGP1 expression in radical 
prostatectomy (RP) specimens. More recently, Lapointe et al. [139] reported a combination of 
immunohistology for AZGP1 and RNA in situ hybridisation for hCAP-D3 expression in tissues from 
225 RP specimens which distinguished even more clearly those patients whose tumours would recur 
and those whose would not (p = 0.0002). Loss of both hCAP-D3 and AZGP1 expression was 
associated with the worst outcomes whereas expression of both markers indicated a very low 
recurrence rate raising the potential for identifying those patients better suited to an active surveillance 
protocol than an active treatment approach with curative intent.  
8.2. Prostatic Acid Phosphatase (PAcP) 
Prior to the introduction of serum PSA, PAcP was used widely to indicate advanced PCa, but fell 
into disuse. However, a number of publications have promoted a renewed role for this enzyme as a 
prognostic indicator in early disease. Moul et al. [140] reported on 295 patients who underwent RP and 
compared the value of pre-treatment serum PSA and PAcP. The Kaplan-Meier disease-free survival rate 
at 4 years was 78.8% for men with a PAcP < 3 ng/mL and 38.8% for those with PAcP ≥ 3 ng/mL, 
which was significant overall (p < 0.001) and, when pre-treatment PSA was <10 ng/mL  
(p = 0.047), ≥10 ng/mL (p = 0.012). They concluded that PAcP testing added prognostic information 
to pre-treatment PSA values and that PAcP was an independent predictor of recurrence [140].  
More recently, Han et al. [141] reviewed pre-operative PAcP levels in 1681 men who proceeded to 
RP and confirmed that PAcP was an independent predictor of tumour recurrence (p < 0.001). Most 
recently Fang et al. [142] examined case histories of 193 patients with clinically localized PCa, a 
Gleason score ≥7 and/or a PSA level of ≥10 ng/mL treated with 103Pd brachytherapy and supplemental 
external beam radiotherapy (EBRT) between 1992 and 1996. The 10-year cause-specific survival 
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(CSS) rate for patients with a pre-treatment PAcP level < 1.5, 1.5–2.4 and ≥2.5 U/L was 93%, 87%, 
and 75%, respectively (P = 0.013). The 10-year CSS rate for patients with a PSA level < 10, 10–20, 
and >20 ng/mL was 92%, 76%, and 83%, respectively (P = 0.393). On Cox multivariate regression 
analysis, PAcP (hazard ratio 1.31, P < 0.0001) and Gleason score (hazard ratio 2.37, P = 0.0007) were 
associated with CSS. PSA was not predictive of CSS (P = 0.393) but PAcP was a stronger predictor of 
CSS than PSA or Gleason score these men with higher risk PCa. 
9. Multiple Markers  
In a recent study of 423 consecutive patients treated with radical prostatectomy for clinically 
localized PCa, pre-operative plasma levels of Endoglin, interleukin-6 (IL-6), interleukin-6 soluble 
receptor (IL-6sR), transforming growth factor-beta1 (TGF-beta1), urokinase plasminogen activator 
(uPA), urokinase plasminogen inhibitor-1 (PAI-1), urokinase plasminogen receptor (uPAR), vascular 
cell adhesion molecule-1 (VCAM1), and VEGF were measured using commercially available enzyme 
immunoassays. Plasma IL-6 (P = 0.03), IL-6sR (P < 0.001), TGF-beta1 (P = 0.005), and V-CAM1  
(P = 0.01) achieved independent predictor status after adjusting for the effects of standard post-
operative features. After stepwise backward variable elimination, a model relying on RP Gleason sum, 
IL-6sR, TGF-beta1, VCAM1, and uPA improved the predictive accuracy of the standard post-
operative nomogram model by a modest 4%. The long-term follow-up of these patients will be of 
particular interest [143]. 
9.1. Annexin A3 (ANXA3) 
ANXA3, a recently identified PCa biomarker, has an inverse relationship to PCa progression and 
can be detected in the urine of PCa patients [144]. ANXA3 belongs to a family of calcium and 
phospholipid binding proteins that are implicated in cell differentiation and migration, 
immunomodulation, bone formation and mineralization in PCa metastasis [145]. ANXA3 has an 
inverse relationship to cancer and the immunhistochemical staining in prostatic tissue correlates with 
disease progression, Gleason score and malignancy [144]. The presence of ANXA3 in urinary 
exosomes and prostasomes might be the reason for its remarkable stability in urine [144,147]. ANXA3 
has been quantified by western blot in the urine samples of patients with negative DRE findings and 
low total PSA (2–10 ng/mL−1), which is the clinically relevant group facing the biopsy dilemma. 
Combined readouts of PSA and urinary ANXA3 gave the best results with the Area Under the 
Receiver Operating Curve (AUROC) of 0.82 for a total PSA range of 2–6 ng/mL−1, 0.83 for a total 
PSA range of 4–10 ng/mL−1 and 0.81 in all patients [147].  
10. MicroRNA Profiling  
MicroRNAs (miRs) are small non-coding RNA molecules with a length of 21–25 nucleotides. They 
are mostly located within inter-genic chromosomal regions and can be found as solitary or clustered 
gene units. MiRs post-transcriptionally regulate gene expression by binding to complementary 
sequences within the 3’UTR of mRNAs. In most cases annealing leads to a modest down regulation of 
gene expression, although a few upregulating miRs have been described [148]. The first 6 to 8 bases of 
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a miR direct its targeting and so each species may bind up to thousands of mRNAs. Very recently, 
researchers have demonstrated that not only can miRs indirectly disable gene function by associating 
with mRNAs, they can silence genes directly by adding methlyl groups and it has been proposed that 
epigenetic silencing by DNA methylation depends on the ratio of miRNA to its target RNA [149]. 
Profiling of PCa cell lines and specimens has been performed for miR expression. The first 
dedicated report by Porkka et al. [150] found expression of many species and that their expression 
varied with malignancy and with the cell’s androgen receptor status. Follow up reports have confirmed 
this finding and extended the profiling of prostate-specific miRs [151]. Evidence to date suggests that 
many miRs with altered expression in PCa are generic to malignancy. This includes over expression of 
miR-21 (which is known to suppress members of the p53 network [152,153], over expression of miRs-
15a and 15b, and loss of miRs 145/34c/221 and 222. The expression of these miRs appears to be 
androgen dependent (in part) and results from chromosomal and epigenetic alterations. Few studies 
have assessed the translational use of these miRs [154,155].  
11. Metabonomics/Metabolomics 
Metabonomics/metalolomics involves the study of metabolites in a biological sample on a global 
scale, with the aim of understanding its metabolic profile and correlating it with a biological, 
physiological or clinical state. In oncology the identification of metabolites that have been observed to 
be different, and characteristically so in PCa compared with non-malignant prostates, has the potential 
to lead to the discovery of biomarkers that are useful for diagnosis and prognosis as well as for 
monitoring effectiveness of therapy. It has been known for many years that citrate and its preferred 
prostatic cation zinc are reduced in PCa epithelial cells, reflected in gland luminal contents and 
prostatic fluid whereas levels of choline and spermine are increased. However, unlike choline, 
spermine is decreased in prostatitis, this condition causing an elevation in serum PSA which can be a 
confounder in the diagnosis of PCa using serum PSA as the sole biomarker [156–161]. 
A variety of mass spectroscopic techniques is available to provide analytical information on small 
molecular metabolites, proteins and other molecules. They include tandem mass spectrometry 
(MS/MS) [162], electron ionisation (EI), electrospray, liquid secondary ionisation mass spectroscopy 
(LSIMS) [163], collision-induced dissociation tandem mass spectrometry (CID/MS/MS) [164] and fast 
atom bombardment mass spectrometry (FAB-MS) [165].  
However, nuclear magnetic resonance spectroscopy (NMR or MRS) [166] is the method most 
commonly reported. Although studies have examined the prostate by in vivo MRS using specially 
designed endo-rectal coils for this purpose, this approach has decreased in recent times with an 
emerging interest in perfoming the MRS analyses on prostatic fluid itself or on biopsies of prostatic 
tissue. A number of recent reviews cover the topic in detail [166–168], thus this section focuses on a 
number of topical contributions and on the most recent developments. 
Using MRS, Lynch and Nicholson [169] examined prostatic fluid from 26 patients (10 BPH, 4 PCas 
and 12 controls) by prostatic massage and from ejaculate from 11 men with vasal aplasia. They 
reported significantly lower citrate: spermine ratios in PCa (p < 0.02) and that findings from ejaculate 
paralleled those obtained following prostatic massage. Also using MRS a difference in citrate levels 
between seminal fluid from 3 patients with PCa compared with specimens from non-PCa donors, was 
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demonstrated by Averna et al. [170] who subsequently confirmed this in a study of 61 participants, of 
whom 16 without and 21 with PCa donated seminal fluid, and 17 without and 7 with PCa donated 
expressed prostatic secretions. Mean citrate levels compared with those from controls were 2.7-fold 
lower in patients with PCa for semen (132.2 ± 30.1 vs. 48.0 ± 7.9 mM, p < 0.05) and expressed 
prostatic secretions [171]. Similarly, Serkova et al. [172] reported that the concentrations of citrate, 
spermine and myo-inositol in human expressed prostatic secretions are age-independent markers of 
PCa. The median concentrations of all three metabolites were significantly decreased in PCa subjects 
(n = 52) when compared with healthy controls (n = 26), with citrate decreasing from 349 mM to 
114 mM (p < 0.0001), spermine decreasing from 57 mM to 27 mM (p < 0.002) and myo-inositol 
decreasing from 21 mM to 7 mM (p < 0.0001). These three markers were highly predictive of PCa 
with AUROC values of 0.89 for citrate, 0.87 for myo-inositol, and 0.79 for spermine. In addition, some 
other metabolites such as pyroglutamate and uracil [173,174] continue to emerge as potential 
biomarkers to indicate the presence of PCa and its prognosis. 
In recent years a number of reports have emerged that use high-resolution magic angle spinning 
(HR-MAS) proton NMR spectroscopy to analyse the metabolite content in intact human prostate tissue 
samples obtained via biopsy or following surgery. As HR-MAS MRS is non-destructive, NMR and 
histopathological data can in principle be obtained for the same sample [175,176]. For example, the 
concentration of citrate (r = 0.763, p < 0.001) and spermine (r = 0.604, p < 0.018), measured by HR-
MAS MRS, has been shown to correlate with the volume percentage of normal, healthy prostatic 
epithelial cells assessed histologically on the same samples [175]. This is physiologically significant, 
as spermine is a proposed endogeneous inhibitor to PCa growth, and the findings mirror solution MRS 
results [173], as well as other HR-MAS changes reflecting a decrease in spermine and other 
polyamines in PCa.  
In two contributions, Swanson et al. [176,177] observed different metabolite profiles in healthy 
glandular and stromal tissue compared with PCa in post-surgical prostate samples using HR-MAS 
MRS. Healthy glandular tissue contained significantly higher levels of citrate (43.1 ± 21.2 mmol/kg) 
and polyamines (PA) (18.5 ± 15.6 mmol/kg), and lower levels of the choline-containing  
compounds choline (3.52 ± 1.44 mmol/kg), phosphocholine (PC) and glycerophosphocholine (GPC)  
([t-choline]mean = 7.06 ± 2.36 mmol/kg) than PCa tissue ([Citrate]mean = 19.6 ± 12.7 mmol/kg, p < 0.01; 
[PA]mean = 5.28 ± 5.44 mmol/kg, p < 0.01; [t-choline]mean = 13.8 ± 7.4 mmol/kg, p < 0.01). Healthy 
stromal tissue contained lower levels of choline compounds ([t-choline]mean = 7.04 ± 3.10 mmol/kg,  
p < 0.01) than PCa, but was similarly low in citrate ([Citrate]mean = 16.1 ± 5.6 mmol/kg) and polyamines 
([PA]mean = 3.15 ± 1.81 mmol/kg) [177]. In addition, levels of taurine, myo-inositol and scyllo-inositol 
were higher in PCa than either healthy tissue component [176]. Remarkably, larger increases in choline 
and decreases in citrate and polyamines (p = 0.05) correlated with more aggressive cancers [176]. 
Using an improved quantitation method by combining HR-MAS MRS with T1 and T2 relaxation times 
optimisation and internal concentration standards, Swanson et al. [177] confirmed their earlier 
observations [176]. In addition, they observed elevated concentrations of lactate (69.8 ± 27.1 mmol/kg, 
p < 0.01) and alanine (12.6 ± 6.8 mmol/kg, p < 0.01) in PCa compared with healthy glandular or 
stromal tissue [177]. Elevated levels of lactate (1.59 ± 0.61 mmol/kg, p < 0.0001) and alanine  
(0.26 ± 0.07 mmol/kg, p < 0.0001) in PCa versus healthy samples ([lactate]mean = 0.61 ± 0.28 mmol/kg; 
[Ala]mean = 0.14 ± 0.06 mmol/kg) were also recently confirmed by combining HR-MAS MRS with the 
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electronic reference to access in vivo concentrations (ERETIC) method [178]
 
as external concentration 
standard on TRUS-guided biopsy samples [179].
 
Finally, HR-MAS MRS can be combined with the 
use of 
13
C-labeled substrates as probes to characterise the various metabolic pathways involved in PCa 
in greater detail [180,181]. 
As new biomarkers for PCa are discovered, it is highly likely that newer and more sensitive 
methods of detection promise to reveal even more markers in this technology-driven discipline. For 
example a recent study of metabolite profiles in urine, blood plasma and surgical tissue samples of 
benign, PCa and metastatic PCa, characterised levels of a large number of metabolites by LC-MS and 
GC-MS, and found that sarcosine levels were increased in PCa (p = 0.0004 in urine sediments, and  
p = 0.0025 in urine supernatants) and the increase correlated with the invasiveness of the cancer [181]. 
Indeed, the mere addition of exogenous sarcosine caused benign prostate epithelial cells to assume an 
invasive phenotype.  
In the same vein, a combination of different analytical techniques with different strengths that 
complement each other is likely make the process of biomarker discovery more robust. The successful 
route to future PCa biomarker discovery will involve a combination of different techniques and hinges 
on the integration of information gained from different tissues (urine, EPF, plasma, biopsies) different 
analytical techniques (MRS and MS) and even different hierarchical levels (genomics, proteomics and 
metabolomics). 
12. Conclusions  
It is expected that, when accurate markers for detection become established in routine clinical 
practice, those patients with normal marker profiles will be able to be spared TRUS biopsies with the 
accompanying potential for untoward effects. If these men are considered to be at-risk of developing 
PCa subsequently, non-invasive testing for abnormal marker profiles will be able to be repeated, as 
appropriate. By contrast, an abnormal detection marker profile indicating the presence of tumour 
would select patients for prognostic profiling and prostatic biopsies. A favourable prognostic profile 
would increase confidence in pursuance of an active surveillance or close observation management 
strategy. On the other hand, a most unfavourable prognostic profile would indicate a very high 
likelihood that the disease is no longer localised and is expected to be already micro-metastatic. Thus, 
the advent of reliable markers for detection and prognosis promises to facilitate tailored management 
to individuals with levels of confidence not currently available. At this point in time, it is evident that 
no one marker by itself is able to accurately detect all cancers with 100% sensitivity and specificity, let 
alone reliably predict outcome, so there is a move to include several markers to improve detection rates. 
Currently, this usually involves total serum PSA, amongst others, with the most commonly used 
molecular marker PCA3, testing for which is available commercially. 
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